TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06224413: A Study of Participants With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel

Sponsor: Genetix Biotherapeutics Inc. · Phase: PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 120 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$16,480,000

Rescue Site Savings

+$10,866,500

Unlock Full NCT06224413 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06224413 Rescue Dossier →